massimaux | 10 points
Scientific Consensus By NIH, FDA and WHO Regarding Monoclonal Antibodies, Convalescent Plasma, Remdesivir and IvermectinIt is both fascinating and admirable to see how the most influential health authorities in the world have come to scientific consensus on several novel and existing drugs/therapies. Science is objective regardless of who interprets it, right?
Casirivimab+Imdevimab (monoclonal antibodies by Regeneron)
NIH: neither for nor against
FDA: emergency use authorization to Regeneron
Bamlanivimab (monoclonal antibody by Eli Lilly)
NIH: neither for nor against
FDA: emergency use authorization to Eli Lilly
Convalescent plasma
NIH: neither for nor against
FDA: emergency use authorization
Remdesivir
NIH: FOR use
FDA: FOR use
WHO: AGAINST use
Ivermectin
NIH: neither for nor against
FDA: AGAINST use. Ignores all in-vivo studies.
[-] giddyrobin | 5 points | Jan 19 2021 20:01:48
I am utterly stunned how hospitals and doctors can sleep at night knowing they have sent SO MANY PEOPLE to their deaths, hiding their eyes from this information.
"FLCCC responded to the "modification" of NIH COVID-19 Treatment Guidelines Panel decision on Ivermectin use:
...we are disappointed by the Panel’s hesitancy to make a recommendation in support of ivermectin, one of the safest, low-cost, and widely available drugs in the history of medicine. While we are thankful for the commitment made to closely monitor the findings of RCT’s near to completion, we struggle to identify an explanation for this level of cautiousness in the setting of escalating and uncontrolled case counts, hospitalizations, and deaths from COVID-19.
FLCCC Alliance Response to the NIH Guideline Committee Recommendation from Jan 14, 2021 on the use of Ivermectin in COVID-19 - Jan 18, 2021 (covid19criticalcare.com)"
permalink